Emerging drugs for hyperlipidemia

Bibliography

• Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994;7:7S
   PubMedGoogle Scholar
• Wilson PW, D'Agostino RB, Levy D, Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837
   PubMed Web of Science ®Google Scholar
• American Heart Association Statistical Fact Sheet-Risk Factors; 2009 update
   Google Scholar
• Ridker PM, Danielson E, Fonseca FAH, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER study group). N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (West of Scotland Coronary Study Prevention Group). N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandanavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTT-LLA). Lancet 2003;361:1149-58
   PubMed Web of Science ®Google Scholar
• Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106:3143
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER, Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46
   PubMed Web of Science ®Google Scholar
• Shih PT, Elices MJ, Fang ZT, Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activatingß1 integrin. J Clin Invest 1999;103:613
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Hislop C, McConnell D, Effects of a selective inhibitor of secretory phospholipase A2 on low density lipoproteins and inflammatory pathways. Lancet 2009;373:649-58
   PubMed Web of Science ®Google Scholar
• Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001;86:386
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Shott S, Tangney CC. Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. Atherosclerosis 2002;161:433
   PubMed Web of Science ®Google Scholar
• Stamos TD, Rosenson RS. Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis 1999;146:161
   PubMed Web of Science ®Google Scholar
• Duverger N, Kruth H, Emmanuel F, Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996;94:713
   PubMed Web of Science ®Google Scholar
• Shah PK, Kaul S, Nilsson J, Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001;104:2376
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brewer HB Jr, Chapman MJ, Cholesterol ester transfer protein: a novel for raising HDL and inhibiting atherosclerosis. Atheroscler Thromb Vasc Biol 2003;23:160-7
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRossa JC, ; for the Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell PM, Collins R, ; for CTT. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP, The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102(Suppl):1K-34K
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Brewer HB Jr, Leitersdorf E, Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate consensus group. Am J Cardiol 1998;81(7):912-17
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J, Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98(19):2088-93
   PubMed Web of Science ®Google Scholar
• WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the committee of Principal Investigators. Lancet 1984;2(8403):600-4
   PubMedGoogle Scholar
• Saha SA, Kizhakepunnur LG, Bahekar A, The role of fibrates in the prevention of cardiovascular disease–a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007;154(5):943-53
   PubMed Web of Science ®Google Scholar
• Magarian GJ, Lucas LM, Colley C. Gemfibrozil-induced myopathy. Arch Intern Med 1991;151(9):1873-4
   PubMed Web of Science ®Google Scholar
• Miller DB, Spence JD. Clinical pharmacokinetics of fibric derivatives (fibrates). Clin Pharmacokinet 1998;34(2):155-62
   PubMed Web of Science ®Google Scholar
• Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264(1):71-5
   PubMed Web of Science ®Google Scholar
• Grundy SM, Mok HY, Zech L, Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981;22(1):24-36
   PubMed Web of Science ®Google Scholar
• Illingworth DR, Stein EA, Mitchel YB, Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994;154(14):1586-95
   PubMed Web of Science ®Google Scholar
• Probstfield JL, Hunninghake DB. Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Arch Intern Med 1994;154:1557
   PubMed Web of Science ®Google Scholar
• Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin dependent diabetes mellitus. JAMA 1990;264(6):723-6
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med 2009;361:2180-3
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Todd CV, Stanek EJ, Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
   PubMed Web of Science ®Google Scholar
• Wetterau JR, Zilversmit DB. A triglyceride and cholesteryl ester transfer protein associated with liver microsomes. J Biol Chem 1984;259:10863-6
   PubMed Web of Science ®Google Scholar
• Wetterau JR, Combs KA, Spinner SN, Protein disulfide isomerase is a component of the microsomal triglyceride transfer protein complex. J Biol Chem 1990;265:9800-7
   PubMed Web of Science ®Google Scholar
• Wetterau JR, Aggerbeck LP, Bouma ME, Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992;258:999-1001
   PubMed Web of Science ®Google Scholar
• Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Ann Rev Nutr 2000;20:663-97
   PubMed Web of Science ®Google Scholar
• Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 2003;44:22-32
   PubMed Web of Science ®Google Scholar
• Hussain MM, Bakillah A. New approaches to target microsomal triglyceride transfer protein. Curr Opin Lipidol 2008;19:572-8
   PubMed Web of Science ®Google Scholar
• Wetterau JR, Gregg RE, Harrity TW, An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998;282:751-4
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Miwa S, Kodama H, Hepatic and intestinal changes in rats treated with T-0126, a microsomal triglyceride transfer protein (MTP) inhibitor. J Toxicol Sci 2007;32:161-77
   PubMedGoogle Scholar
• Chandler CE, Wilder DE, Pettini JL, CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003;44:1887-901
   PubMed Web of Science ®Google Scholar
• Ueshima K, kihisa-Umeno H, Nagayoshi A, Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull 2005;28:247-52
   PubMed Web of Science ®Google Scholar
• Crooke RM, Graham MJ, Lemonidis KM, An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005;46:872-84
   Google Scholar
• Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009;50:S172-7
   PubMed Web of Science ®Google Scholar
• Rosenson RR, Hislop C, Elliot M, Abstract 1928: effect of a selective inhibitor of secretory phospholipase A2 on low density and very low density lipoprotein subclasses in stable coronary heart disease patients–PLASMA 2 trial. Circulation 2008;118:S_406-7
   Google Scholar
• Shinomiya M, Shirai K, Saito Y, Inhibition of intimal thickening of the carotid artery of rabbits and of outgrowth of explants of aorta by probucol. Atherosclerosis 1992;97:143-8
   PubMed Web of Science ®Google Scholar
• Ishizaka N, Kurokawa K, Taguchi J, Inhibitory effect of a single local probucol administration on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 1995;118:53-6
   PubMed Web of Science ®Google Scholar
• Tardif JC, Cote G, Lesperance J, Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337:365-72
   PubMed Web of Science ®Google Scholar
• Yokoi H, Daida H, Kuwabara Y, Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997;30:855-62
   PubMed Web of Science ®Google Scholar
• Sawayama Y, Shimizu C, Maeda N, Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002;39:610-16
   PubMed Web of Science ®Google Scholar
• Tardif J, Gregoire J, Schwartz L, Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552-8
   PubMed Web of Science ®Google Scholar
• Otvos JD, Collin D, Freedman DS, Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-63
   PubMed Web of Science ®Google Scholar
• Pitt B, Mancini GB, Rosman HS, Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995;26(5):1133-9
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Davidson M, Furberg CD, Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31(4):811-22
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2006;295:2581-6
   Google Scholar
• AstraZeneca discontinues development of GALIDA (Tesaglitazar). Astrazeneca 2006-05-04
   Google Scholar
• Abrams JJ, Grundy SM. Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J Lipid Res 1981;22:323-38
   PubMed Web of Science ®Google Scholar
• Morkin E, Ladenson P, Goldman S, Thyroid hormone analogues for the treatment of hypercholesterolemia and heart failure: past, present, and future prospects. J Mol Cell Cardiol 2004;37:1137-46
   PubMed Web of Science ®Google Scholar
• Salter AM, Hayashi R, Al-Seeni M, Effects of hypothyroidism and high-fat feeding on mRNA concentrations for the low-density lipoprotein receptor and on acyl-CoA: cholesterol acyltransferase activities in rat liver. Biochem J 1991;276:825-32
   PubMed Web of Science ®Google Scholar
• Cuchel M, Bloedon LT, Szapary PO, Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148-56
   PubMed Web of Science ®Google Scholar
• Samaha FF, McKenney J, Bloedon LT, Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008;5:497-505
   Google Scholar
• Sorbera LA, Martin L, Silvestre J, Implitapide. Drugs Fut 2000;25:1138-44
   Web of Science ®Google Scholar
• Chandler CE, Wilder DE, Pettini JL, CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003;44:1887-901
   PubMed Web of Science ®Google Scholar
• Barter PJ, Nicholls S, Rye KA, ; for the ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21): 2109-22[s5]
   Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L, Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620
   PubMed Web of Science ®Google Scholar
• Vergeer M, Bots ML, van Leuven SI, Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008;118:2515
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Brennan DM, Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008;118:2506
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomised phase II dose response study. Circulation 2002;105:2159-65
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, de Grooth GJ, Kawamura H, Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8
   PubMed Web of Science ®Google Scholar
• Stein EA, Stroes ESG, Steiner G, Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from 5 phase II clinical trials. Am J Cardiol 2009;104(1):82-91
   Google Scholar
• Krishna R, Anderson MS, Bergman AJ, Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907
   PubMed Web of Science ®Google Scholar
• Bloomfield D, Carlson GL, Sapre A, Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009;157:352
   PubMed Web of Science ®Google Scholar
• Ameli S, Hultgardh-Nilsson A, Cercek B, Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994;90:1935
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Wedel MK, Baker BF, Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729
   PubMed Web of Science ®Google Scholar
• Visser ME, Akdim F, Tribble DL, Effect of ApoB synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. In press
   PubMed Web of Science ®Google Scholar
• Raal EF, Santos RD, Blom DJ, Mipomersen an apolipoprotein B synthesis inhibitor for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Lancet 2010;375(9719):998-1006
   PubMed Web of Science ®Google Scholar
• Press release Genzyme February 2010
   Google Scholar
• Tardif JC, Gregoire J, L'Allier PL, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675
   PubMed Web of Science ®Google Scholar
• Fraser H, Hislop C, Christie RM, Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol 2009;53:60-5
   PubMed Web of Science ®Google Scholar
• Shaposhnik Z, Wang X, Trias J, The synergistic inhibition of atherogenesis in ApoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res 2008;50:623-9
   PubMed Web of Science ®Google Scholar
• Maccubin D, Koren M, Davidson M, Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009;104:74-81
   PubMed Web of Science ®Google Scholar
• Maccubin D, Bays HE, Olsson AG, Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidemia. Int J Clin Practice 2008;62(12):1959-70
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabes JP, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6
   PubMed Web of Science ®Google Scholar
• Cohen J, Pertsemlidis A, Kotowski IK, Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37(2):161-5
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-73
   PubMed Web of Science ®Google Scholar
• Kotowski IK, Pertsemlidis A, Luke R, A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Human Genet 2006;78:410-22
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, Schwartz L, ; for the Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552-8
   PubMed Web of Science ®Google Scholar
• Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004;65:419-22
   PubMed Web of Science ®Google Scholar
• Berge KE, Ose L, Leren TP. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Artrerioscler Thromb Vasc Biol 2006;26:1094-100
   PubMed Web of Science ®Google Scholar
• Henry RR, Lincoff AM, Mudaliar S, Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374(9684):96-8
   PubMed Web of Science ®Google Scholar
• Press release Genfit November 23, 2009
   Google Scholar
• Tardif JC, Gregoire J, L'Allier PL, for the Canadian Antioxidant Restenosis Trial (CART-2) Investigators. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 2008;197:480-6
   PubMed Web of Science ®Google Scholar
• Tardif JC, McMurray JJ, Klug E, Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, doubleblind, placebo-controlled trial. Lancet 2008;371:1761-8
   PubMed Web of Science ®Google Scholar
• Ladenson PW, Kristensen JD, Ridgway EC, Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010;362:906-16
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvistatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandanavian Simvistatin Survival Study (4S). Lancet 1994;344(8934):1383-9
   PubMedGoogle Scholar